Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2005, Issue 3, Pages 287-290
Research article

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis

1Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, IL 60612, USA
2Department of Biochemistry, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
3Department of Urology, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
4Department of Urology, University of Illinois at Chicago, Chicago, IL 60612, USA

Received 26 May 2004; Revised 27 July 2004; Accepted 9 October 2004

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Our aim is the identification and correlation of changes in tumor-associated protein expression which results from therapy. LNCaP tumors, excised from nude mice treated either by orchiectomy or with the chemotherapeutic agent paclitaxel, were evaluated for the expression of proteins and receptors associated with growth, differentiation, and angiogenesis using immunohistologic procedures. Compared to untreated control tumors, both treatments reduced the expression of vascular endothelial growth factor (VEGF), prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), androgen receptor (AR), and epidermal growth factor receptor (EGFR). The effect of paclitaxel treatment on AR expression was the most significant (P=.005). Of particular interest was identifying a significant correlation (P<.000801) between PSMA and VEGF expression regardless of treatment modality. These altered expressions suggest that PSMA may also be a marker for angiogenesis and could represent a target for deliverable agents recognizing either prostatic tumors or endothelial development. Cell surface PSMA would then present a unique target for treatment of patients early in their development of prostatic metastases.